Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020

Authors

  • Keita Morikane Yamagata University, Yamagata, Japan
  • Naohito Satoh Yamagata University, Yamagata, Japan
  • Kanji Hatano Yamagata University, Yamagata, Japan
  • Kazunori Kanouchi Yamagata University, Yamagata, Japan
  • Seiji Kakehata Yamagata University, Yamagata, Japan
  • Shinya Satoh Yamagata University, Yamagata, Japan
  • Timothy Uyeki Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
  • Yoshiyuki Ueno Yamagata University, Yamagata, Japan

DOI:

https://doi.org/10.5365/wpsar.2020.11.3.012

Abstract

We conducted a seroepidemiological study in a northern Japanese prefecture where the incidence of identified COVID-19 cases was low. In June 2020, residual sera from 1009 outpatients were tested for antibody to SARS-CoV-2 by electrochemiluminescence immunoassay.  Five specimens (0.5%) tested positive, suggesting low prevalence of SARS-CoV-2 infections in this population.

References

Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Jun 18. doi: 10.1038/s41591-020-0965-6.

Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 antibody seroprevalence in Santa Clara county, California. MedRxiv. April 30, 2020. https://doi.org/10.1101/2020.04.14.20062463

Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles county, California, on April 10-11, 2020. JAMA. 2020;323:2425-7.

New York State. April 27, 2020. Amid ongoing COVID-19 pandemic, Governor Cuomo announces phase II results of antibody testing study show 14.9% of population has COVID-19 antibodies. https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-announces-phase-ii-results-antibody-testing-study.

Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med 2020 July 21. Doi: 10.1001/jamainternmed.2020.4130

Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020 July 6. Doi: 10.1016/S0140-6736(20)31483-5

Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 Jun 11. doi: 10.1016/S0140-6736(20)31304-0

Downloads

Published

01-02-2021

How to Cite

1.
Morikane K, Satoh N, Hatano K, Kanouchi K, Kakehata S, Satoh S, Uyeki T, Ueno Y. Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020. Western Pac Surveill Response J [Internet]. 2021 Feb. 1 [cited 2026 Mar. 27];12(1). Available from: https://ojs.wpro.who.int/ojs/index.php/wpsar/article/view/795

Issue

Vol. 12 No. 1 (2021): January ‒ March

Section

COVID-19: Brief Report

License

You are free to:

  • Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

When the Licensor is an intergovernmental organization, disputes will be resolved by mediation and arbitration unless otherwise agreed.

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.